293 related articles for article (PubMed ID: 18569395)
21. [Treatment of T-cell prolymphocytic leukemia with monoclonal anti- CD52 antibody (alemtuzumab].
Fløisand Y; Brinch L; Gedde-Dahl T; Tjønnfjord GE
Tidsskr Nor Laegeforen; 2004 Mar; 124(6):768-70. PubMed ID: 15039804
[TBL] [Abstract][Full Text] [Related]
22. Alemtuzumab in B-cell chronic lymphocytic leukemia.
Shapira I; Grossbard ML
Clin Lymphoma; 2004 Mar; 4(4):228-9. PubMed ID: 15072614
[No Abstract] [Full Text] [Related]
23. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies.
Albitar M; Do KA; Johnson MM; Giles FJ; Jilani I; O'Brien S; Cortes J; Thomas D; Rassenti LZ; Kipps TJ; Kantarjian HM; Keating M
Cancer; 2004 Sep; 101(5):999-1008. PubMed ID: 15329909
[TBL] [Abstract][Full Text] [Related]
24. Sustained, durable responses with alemtuzumab in refractory angioimmunoblastic T-cell lymphoma.
Amengual JE; Raphael BG
Leuk Lymphoma; 2010 Jul; 51(7):1347-50. PubMed ID: 20572801
[No Abstract] [Full Text] [Related]
25. Effect of alemtuzumab on neoplastic B cells.
Golay J; Manganini M; Rambaldi A; Introna M
Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
[TBL] [Abstract][Full Text] [Related]
26. Overview of alemtuzumab therapy for the treatment of T-cell lymphomas.
Zinzani PL; Corradini P; Gallamini A; Grossi A; Lazzarino M; Marchetti M; Martelli M; Rossi G; Vitolo U
Leuk Lymphoma; 2012 May; 53(5):789-95. PubMed ID: 21980956
[TBL] [Abstract][Full Text] [Related]
27. Rediscovering alemtuzumab: current and emerging therapeutic roles.
Gribben JG; Hallek M
Br J Haematol; 2009 Mar; 144(6):818-31. PubMed ID: 19183194
[TBL] [Abstract][Full Text] [Related]
28. Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia.
Rezvany MR; Tehrani MJ; Karlsson C; Lundin J; Rabbani H; Osterborg A; Mellstedt H
Br J Haematol; 2006 Nov; 135(4):475-85. PubMed ID: 16995884
[TBL] [Abstract][Full Text] [Related]
29. Monoclonal antibody therapy for central nervous system lymphomas: an emerging treatment paradigm.
Wong ET
Expert Opin Pharmacother; 2005 Jun; 6(7):1107-14. PubMed ID: 15957965
[TBL] [Abstract][Full Text] [Related]
30. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.
Cruz RI; Hernandez-Ilizaliturri FJ; Olejniczak S; Deeb G; Knight J; Wallace P; Thurberg BL; Kennedy W; Czuczman MS
Leuk Lymphoma; 2007 Dec; 48(12):2424-36. PubMed ID: 18067019
[TBL] [Abstract][Full Text] [Related]
31. Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52).
Osterborg A; Werner A; Halapi E; Lundin J; Harmenberg U; Wigzell H; Mellstedt H
Eur J Haematol; 1997 Jan; 58(1):5-13. PubMed ID: 9020367
[TBL] [Abstract][Full Text] [Related]
32. Alemtuzumab, the first monoclonal antibody (MAb) directed against CD52.
Keating M; Hallek M
Med Oncol; 2002; 19 Suppl():S1-2. PubMed ID: 12180486
[No Abstract] [Full Text] [Related]
33. Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models.
Siders WM; Shields J; Garron C; Hu Y; Boutin P; Shankara S; Weber W; Roberts B; Kaplan JM
Leuk Lymphoma; 2010 Jul; 51(7):1293-304. PubMed ID: 20377308
[TBL] [Abstract][Full Text] [Related]
34. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies.
Dyer MJ
Semin Oncol; 1999 Oct; 26(5 Suppl 14):52-7. PubMed ID: 10561018
[TBL] [Abstract][Full Text] [Related]
35. Effective treatment of a peripheral T-cell lymphoma/lymphoepitheloid cell variant (Lennert's lymphoma) refractory to chemotherapy with the CD-52 antibody alemtuzumab.
Zeitlinger MA; Schmidinger M; Zielinski CC; Chott A; Raderer M
Leuk Lymphoma; 2005 May; 46(5):771-4. PubMed ID: 16019517
[TBL] [Abstract][Full Text] [Related]
36. Campath-1H monoclonal antibody therapy.
Flynn JM; Byrd JC
Curr Opin Oncol; 2000 Nov; 12(6):574-81. PubMed ID: 11085457
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia.
Mohan SR; Clemente MJ; Afable M; Cazzolli HN; Bejanyan N; Wlodarski MW; Lichtin AE; Maciejewski JP
Haematologica; 2009 Oct; 94(10):1407-14. PubMed ID: 19794084
[TBL] [Abstract][Full Text] [Related]
38. [Monoclonal antibodies in hematology in 2009].
Bonnet C; Beguin Y; De Prijck B; Witvrouw N; Hustinx R; Fillet G
Rev Med Liege; 2009; 64(5-6):268-73. PubMed ID: 19642457
[TBL] [Abstract][Full Text] [Related]
39. Monoclonal antibodies in the treatment of cancer, Part 1.
Cersosimo RJ
Am J Health Syst Pharm; 2003 Aug; 60(15):1531-48. PubMed ID: 12951753
[TBL] [Abstract][Full Text] [Related]
40. Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia.
Au WY; Lam CC; Chim CS; Pang AW; Kwong YL
Leuk Res; 2005 Oct; 29(10):1213-5. PubMed ID: 16111536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]